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Highlights: 
 Anxiety levels were high in patients with breast and colorectal cancer commencing 
chemotherapy treatment. 
 Both state and trait anxiety declined with treatment progression, contradicting the notion 
of trait stability over time.  
 Trait anxiety was the only significant predictor of state anxiety throughout treatment, 
overshadowing symptom burden effects.  
 Psychosocial/behavioural interventions introduced at pre-chemotherapy could help 
reduce patient anxiety throughout treatment.  
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Abstract  
 
Purpose 
To examine the trajectories and predictors of state and trait anxiety in patients undergoing 
chemotherapy for breast or colorectal cancer.  
 
Methods 
Secondary analysis of data collected as part of a large multi-site longitudinal study. Patients with 
breast or colorectal cancer completed validated scales assessing their state and trait anxiety levels 
(State-Trait Anxiety Inventory) and symptom burden (Rotterdam Symptom Checklist) at the 
beginning of each chemotherapy cycle. Longitudinal mixed model analyses were performed to 
test changes of trait and state anxiety over time and the predictive value of symptom burden and 
patients’ demographic (age, gender) and clinical characteristics (cancer type, stage, 
comorbidities, ECOG performance status). 
 
Results 
Data from 137 patients with breast (60%) or colorectal cancer (40%) were analysed. Linear time 
effects were found for both state (χ2=46.3 [df=3]; p<0.001) and trait anxiety (χ2=17.708 [df=3]; 
p=0.001), with anxiety levels being higher at baseline and gradually decreasing over the course 
of chemotherapy. Symptom burden (β=0.21; SD=0.06; p=0.001) predicted state anxiety 
throughout treatment, but this effect disappeared when accounting for trait anxiety scores before 
the start of chemotherapy (β=0.85; SD=0.05; p<0.001). Patients’ baseline trait anxiety was the 
only significant predictor of anxiety throughout treatment.  
 
Conclusions 
Changes in the generally stable characteristic of trait anxiety indicate the profoundly life-altering 
nature of chemotherapy. The time point before the start of chemotherapy was identified as the 
most anxiety-provoking, calling for interventions to be delivered as early as possible in the 
treatment trajectory. Patients with high trait anxiety and symptom burden may benefit from 
additional support.  
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Introduction 
 Anxiety in patients with cancer is a topic of great importance: previous research shows 
that this particular emotion is not only extremely common in this patient group (Burgess et al., 
2005; Lewis et al., 2014), but it also has far-reaching effects on symptom experiences during 
treatment (Lockefeer and Vries, 2013; Saevarsdottir et al., 2010; Whitford and Olver, 2012), 
treatment compliance (Greer et al., 2008), patient outcomes such as experienced side-effects 
(Van Esch et al., 2011), and even survivorship (García-Torres and Alós, 2014). A useful 
theoretical framework for researching anxiety throughout the course of cancer treatment is 
Spielberger’s anxiety model (Spielberger, 1989; Spielberger et al., 1983), which differentiates 
between state and trait anxiety.  
State anxiety represents a transitory emotional state as a reaction to a particular stressor, 
e.g. being diagnosed with cancer, and fluctuates over time. Trait anxiety, on the other hand, is a 
stable susceptibility or proneness to experience anxiety and is regarded as a vulnerability factor 
for adverse reactions to stress. This distinction has been empirically tested and is consistently 
supported by research with various populations, ranging from psychiatric, psychosomatic, and 
medical patient groups to the general population (Spielberger and Reheiser, 2009). Considering 
this model when investigating the experiences of patients with cancer can help discern the 
influence of patients’ anxiety predisposition and anxiety as a reaction to a stressful life event.  
In the cancer care context, high trait anxiety is often accompanied by poor health status as 
well as negative self-perceptions and expectations for the future (Van Esch et al., 2011). It can 
also act as a precursor for developing symptoms of depression and fatigue (Lockefeer and Vries, 
2013). Of significance is that no study to date has investigated if trait anxiety remains stable 
when undergoing treatment for cancer, as predicted by Spielberger’s theory (Spielberger, 1989; 
Spielberger et al., 1983).  
Unlike trait anxiety, trajectories of state anxiety in patients with cancer have been 
explored in few longitudinal studies. Lewis et al. (2014) repeatedly assessed anxiety levels of 
213 patients with non-metastatic breast cancer undergoing radiotherapy. Within this patient 
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group, initially high anxiety rapidly declined with the start of treatment, suggesting habituation 
effects. In women scheduled to receive chemotherapy for breast cancer, the time point before the 
first treatment cycle was also identified as being the most anxiety-provoking (Jacobsen et al., 
1993). Baseline trait anxiety levels and chemotherapy toxicity contributed significantly to higher 
levels of state anxiety during treatment. This research provides preliminary insight into the 
development of patients’ state anxiety over time, but in qualification, it must be added that state 
anxiety in both studies was only measured with a single-item visual analogue scale instead of a 
validated state anxiety questionnaire based on Spielberger’s conceptualization (Spielberger et al., 
1983). 
Burgess et al. (2010) stress the importance of providing psychological support for 
patients with cancer as anxiety stays elevated even after chemotherapy cessation/completion. 
This however requires a thorough understanding of underlying processes and pre-cursors of 
higher levels of anxiety. Further, untangling the influence of situational factors (e.g. diagnosis, 
treatment commencement, symptom burden) and underlying characteristics of a person (e.g. 
general anxiety predisposition, symptom experience), can help to identify critical time points and 
patient groups most in need for interventions. 
The current analysis aimed to enhance our understanding of the trajectories and 
predictors of both state and trait anxiety in patients with cancer undergoing chemotherapy for 
breast or colorectal cancer, addressing the following research questions:  
a) How do state and trait anxiety levels change over the course of treatment? 
b) Do any demographic (age, gender) or clinical characteristics (cancer type, staging, 
comorbidity, performance status, symptom burden) predict initial levels and/or the 
trajectories of state and trait anxiety over the course of treatment? 
c) Does baseline trait anxiety affect state anxiety over the course of treatment?  
Testing those questions for the specified patient groups is particularly interesting due to a 
number of reasons. Firstly, breast and colorectal cancer are two of the most commonly diagnosed 
forms of cancer (Westlake & Cooper, 2008; Torre et al., 2015). Breast cancer is the most 
prevalent type of cancer in females, with an estimated incidence rate of 44,400 in the UK alone 
(Westlake & Cooper, 2008) and 1.7 million cases per year worldwide (Torre et al., 2015). 
Colorectal cancer is the third most common cancer in males and the second in females, with a 
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yearly incidence rate of 36,200 in the UK (Westlake & Cooper, 2008) and 1.4 million worldwide 
(Torre et al., 2015).  
Considering the experience of both patient groups is useful as previous longitudinal 
research predominantly focused on anxiety in female breast cancer patients (e.g. Burgess et al., 
2005; Jacobsen, Bovbjerg, & Redd, 1993; Lewis et al., 2014; Lim, Kamala Devi, & Ang, 2011; 
Van Esch et al., 2011). On the one hand, this is reasonable as women typically report more 
anxiety problems (McLean & Anderson, 2009), but additionally accounting for male patients in 
this study allows testing of such gender effects. Beyond this, cancer experiences differ for 
different types of cancer and therefore it is advisable to research different patient groups 
(LeMasters, Madhavan, Sambamoorthi, & Kurian, 2013). Finally, considering in particular 
patients undergoing chemotherapy for an exploration of trait and state anxiety suggested itself as 
this treatment causes higher anxiety levels than other treatment types (Lim et al., 2011), possibly 
due to its often distressing and potentially life threatening side effects (Du, Osborne, & Goodwin, 
2008). 
Methods  
Participants and procedures 
Data presented in this article derived from the first phase of a wide-scale, before-and-
after intervention study that was conducted at four health boards across the UK. The overall aim 
of the study was to examine the feasibility and acceptability of the use of the Advanced 
Symptom Management System (ASyMS), a mobile phone-based, real-time, remote patient-
monitoring system to assist with the assessment and management of chemotherapy-related 
toxicity (Kearney et al., 2009).  
The ‘Before Phase’, which was the basis for the secondary data analysis reported in this 
article, focused on the baseline investigation of patients’ experiences of chemotherapy before the 
introduction of the intervention. It involved the longitudinal assessment of patients receiving 
standard care, whereas the ‘After Phase’ collected the same self-reported data from a separate 
group of patients using the ASyMS system while undergoing chemotherapy. A publication with 
respect to the primary analysis is currently in preparation and results concerning the intervention 
are available from the authors. Research Governance and ethical approval were obtained for all 
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parts of this research (East of Scotland Research Ethics Service: REC Reference No 
10/S0501/55). Data was collected for this phase from August 2011 to July 2013.  
Health care professionals at each site approached patients diagnosed with non-metastatic 
breast or colorectal cancer receiving adjuvant chemotherapy treatment aged 18 years or over. 
Written informed consent was obtained from all interested patients. Demographic and clinical 
information was collected for study participants, who also completed a battery of self-report 
questionnaires (see measures) at baseline and with each chemotherapy cycle in a repeated-
measures format for a total six consecutive assessments.  
Measures  
Demographic and clinical characteristics data were assessed at baseline. Participants 
provided basic demographic information regarding their age and gender. The following clinical 
characteristics were obtained reviewing participants’ medical case notes: cancer type and stage, 
type of treatment, chemotherapy cycle length, comorbidities and physical functioning (ECOG 
performance status).  
Anxiety was assessed using the 40-item State-Trait Anxiety Inventory (STAI), a widely 
used measurement of state and trait anxiety (Spielberger, 1989; Spielberger et al., 1983). Each 
subscale consists of 20 items that are rated on a 4-point scale. The total score range for each 
subscale is 20 to 80, higher scores indicating higher anxiety. The STAI has been extensively 
researched in various populations and findings confirm its validity and internal consistency. 
Furthermore, the STAI has been widely used in cancer research (Jacobsen et al., 1993; Lim et al., 
2011; Taoka et al., 2014) and was recommended by an expert panel (including clinicians and 
cancer survivors) for the assessment of anxiety in patients with cancer (Howell et al., 2013). The 
internal consistency of the STAI in this study was good (Cronbach’s alpha throughout treatment 
for state anxiety ranging from 0.94-0.97; for trait anxiety from 0.92-0.96). 
Symptom burden was determined via the Rotterdam Symptom Checklist (RSCL), which 
assesses 30 symptoms reported by patients with cancer (Olschewski et al., 1996). Participants 
rated on a 4-point scale how much physical (e.g. tiredness, nausea) and psychological symptoms 
(e.g. irritability, nervousness) bothered them in the past three days, with higher scores suggesting 
higher symptom levels. Additionally, the scale comprises eight ratings concerning participants’ 
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activity level and overall quality of life, where lower scores indicate higher impairment. The 
RSCL exhibits good psychometric properties as verified across patient populations (de Haes et 
al., 1990). The internal consistency of the RSCL symptom subscale in this study was good 
(Cronbach’s alpha ranging from 0.83-0.88). 
Analyses 
Descriptive statistics for baseline characteristics and the outcome measures at each time-
point were calculated. Furthermore, the development of trait and state anxiety was plotted over 
the course of chemotherapy treatment. Repeated measurements of anxiety and symptom severity 
at different time points resulted in a nested data set, calling for an analysis approach that 
accounts for this higher level clustering of individuals’ ratings by time to avoid type I errors and 
biased parameter estimations (Peugh, 2010; Shek and Ma, 2011). Therefore, longitudinal mixed 
model analyses were used to answer our three research questions as stated above.  
Models that accounted for linear and quadratic time effects were calculated and -2 log 
likelihood tests were employed to identify which model was a better fit to the data. For the final 
conditional models, inter-individual differences were considered modelling the individual change 
parameters (intercept and slope) of anxiety (outcome) as a function of the potential predictors: 
age, gender, cancer type, disease stage, ECOG performance status and comorbidities. Significant 
estimates imply that the change in anxiety over time fluctuates depending on these variables. The 
research questions informed the inclusion of predictor variables.  
To compare participants with lower and higher trait anxiety as measured at baseline with 
the STAI, a median split was performed as no published cut-off scores are available for the 
current sample population. An alpha level of <0.05 was applied for statistical significance tests. 
All analyses were performed in SPSS version 20 (IBM, Chicago, IL) based on restricted 
maximum likelihood estimation. 
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Results 
Participants’ demographic and clinical characteristics  
A total of 140 patients diagnosed with breast or colorectal cancer participated in the study. 
Analysable data were available for 137 participants (breast cancer: 60%; colorectal cancer: 40%) 
as three participants did not provide information on anxiety. Participants’ age ranged from 30 to 
76, with a mean age of 56 years (SD=10.41). Baseline characteristics of all participants are 
summarised in Table 1. Participants were, on average, in their mid-fifties, diagnosed with stage 
two or three cancer and suffering from at least one comorbidity.  
Mainly female participants (98%; n=79) were recruited for the breast cancer group, 
whereas the male-female proportion was well-balanced for patients with colorectal cancer. 
Comparing the two sub-groups, patients with colorectal cancer were typically older (Z=-4.24; 
p<0.001), suffered from more comorbid illnesses (χ2=12.97; p=0.002), their cancer stage was 
more advanced (χ2=22.58; p<0.001) and their performance status was rated lower than their 
counterparts with breast cancer (χ2=11.99; p=0.002). However, there was no group difference 
with regard to symptom burden as reflected by baseline RSCL scores (Z=-0.95; p=0.344).  
Prevalence of state and trait anxiety  
Pre-chemotherapy anxiety scores are summarized in Table 1. There was no significant 
difference among trait (Z=-0.86; p=0.392) or state anxiety (Z=-1.47; p=0.141) for patients with 
colorectal and breast cancer. The median split (Mdn=34) allocated 70 (53.4%) participants to a 
lower trait anxiety group (STAI trait≤34) and 61 (46.6%) to a higher trait anxiety group (STAI 
trait>34), allowing to compare participants with lower and higher trait anxiety in the following 
analyses.  
Changes of state and trait anxiety over time   
Table 2 provides a summary of those changes over time, reporting means and standard 
deviations of changes for each chemotherapy cycle compared to baseline. Mixed analyses (Table 
3) revealed that including linear time effects significantly improved the model’s fit for the 
current sample compared to a means only models for both, state (χ2=46.3 [df=3]; p<0.001) and 
trait anxiety (χ2=17.708 [df=3]; p=0.001). Modelling squared time effects did not result in 
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models with a better fit to the data than the presented linear models, evidence by an increase of 
the -2 log likelihood estimates.  
Taking into account negative time coefficients for state (β= -0.84; SD=0.20; p<0.001) 
and trait anxiety (β= -0.33; SD=0.12; p=0.008), this means that both types of anxiety gradually 
decreased over the course of chemotherapy in a linear manner. Changes in state anxiety were 
more pronounced than changes in trait anxiety, even though both shifted significantly (Figure 1). 
Variance component analysis suggested that after accounting for time effects, enough individual 
variance was left to explore the influence of other potential predictor variables on state anxiety 
levels throughout treatment and on baseline trait anxiety scores (Table 3). 
Predictors of anxiety levels over time  
Symptom burden as measured with the RSCL increased with chemotherapy progression 
and symptom scores reached a peak at the final assessment time point (Table 2). Accounting for 
participants’ gender, cancer type, age, cancer stage, comorbidities, ECOG status and RSCL 
symptom scores significantly improved the models’ fit (χ2=262.974 [df=13]; p<0.001), but only 
the symptom scores were associated with state anxiety. The higher the participants’ symptom 
burden during treatment, the higher their state anxiety levels (β=0.21; SD=0.06; p=0.001).  
Similar results were obtained for trait anxiety: accounting for listed predictor variables 
resulted in a model with a better fit (χ2=211.435 [df=13]; p<0.001) compared to the 
unconditional model and experienced symptom burden as measured with the RSCL was 
associated with baseline trait anxiety ratings (β=0.18; SD=0.05; p<0.001). Participants, who at 
baseline indicated suffering from more symptoms (e.g. carry-over from previous treatments such 
as surgery) also rated their trait anxiety higher at this point compared to those without similar 
complaints. 
Baseline trait anxiety as predictor of state anxiety during chemotherapy 
treatment  
Modelling state anxiety during chemotherapy based on group membership according to 
the median split while adjusting for participant characteristics (age, gender, cancer type, stage, 
comorbidities, ECOG performance status) and experienced symptoms (RSCL scores) highlighted 
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the importance of baseline trait anxiety for the trajectory of state anxiety. None of the participant 
characteristics predicted state anxiety scores over treatment in the current sample except initial 
trait anxiety ratings (β=0.85; SD=0.05; p<0.001). Even the previously described effect of 
experienced symptom burden as measured with the RSCL disappeared (β=0.05; SD=0.05; 
p=0.274). Baseline trait anxiety therefore mediated any effects of experienced symptoms on 
patients’ state anxiety throughout treatment. Participants from the higher trait anxiety group 
experienced higher levels of state anxiety throughout chemotherapy treatment compared to 
participants with initial low trait anxiety scores. 
Discussion 
The present study found linear time effects on anxiety in patients undergoing 
chemotherapy for breast and colorectal cancer: patients started out with high anxiety, which 
declined with treatment progression. This trajectory applied to both state and trait anxiety. 
Symptom burden was the only variable with a statistically significant effect on initial trait 
anxiety levels. Symptom burden was also identified as a significant predictor for state anxiety 
throughout chemotherapy, but this effect was cancelled out when accounting for baseline trait 
anxiety. The latter significantly predicted patients’ state anxiety levels throughout treatment. 
The described trend, i.e. a decline of anxiety levels when undergoing chemotherapy, 
could be due to the high overall performance status of the current patient sample (71% ECOG 
Performance Status Grad 0). This clinical characteristic has been shown to be associated with 
low anxiety (Bodurka-Bevers et al., 2000), possibly because such patients do not develop as 
many side-effects as patients with lower performance status. Another explanation for the 
observed developments might be adaption: after the initial fear of unfamiliar treatment 
procedures, patients became more acquainted with chemotherapy, reducing anxieties. This 
argument is backed up by the observation that receiving relevant information seems important in 
facilitating patients' adaptation (Ream and Richardson, 1996).  
Lien et al. (2009) found similar adaption processes as evident in the current sample in 
patients treated with surgery for cancer. They highlighted social support as an important driver 
for adjustment and anxiety attenuation. Negative correlations have been reported between 
patients’ self-efficacy and anxiety ratings when undergoing radiotherapy (Cohen, 2014), 
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suggesting that gaining expertise and confidence in their coping abilities could reduce patients’ 
worries over the course of treatment. Those factors might also play a role in chemotherapy 
treatment and may have contributed to the observed downtrend in anxiety ratings.  
For state anxiety, the trajectory and predictors investigated in the current study mirror 
findings from previous research.  Jacobsen et al. (1993) reported that anxiety in women receiving 
chemotherapy for breast cancer was highest before their first cycle and that trait anxiety and 
side-effects predicted anxiety later on. A cross-sectional survey of men with prostate cancer 
undergoing radical treatment found high correlations of state and trait anxiety and a decline in 
state anxiety over time (Taoka et al., 2014). Though age is regularly ascribed as an effect on 
anxiety during cancer treatment (Cohen, 2014; Jacobsen et al., 1993), this was not the case in the 
current sample although a wide age range was covered. We found that rather physical symptoms 
experienced while undergoing chemotherapy influence a persons’ general vulnerability to react 
anxiously (state anxiety), explaining why interventions that address chemotherapy side-effects 
are also effective in reducing anxiety (Vasterling et al., 1993; Yoo et al., 2005). However, when 
symptom burden and trait anxiety were regressed together on state anxiety levels, the situational 
anxiogenic effects of symptom burden disappeared. This finding raises the hypothesis that 
personality traits may be stronger influential variables of stress response than situational factors, 
such as chemotherapy symptom burden (Du, Osborne, & Goodwin, 2008).  
In addition, the significant correlation of trait anxiety with perceived symptom burden at 
baseline could also be interpreted as patient ‘proneness’ to over-reporting/experiencing long-
standing physical symptoms, which may be true for certain personality types (Shun et al., 2014; 
Zhang et al., 2016). It is intriguing to hypothesize that the link between personality-driven trait 
anxiety levels and situational anxiety levels during chemotherapy may be mediated by worry 
about anticipated physical symptoms and the associated burden, or anxiety somatization that is 
manifested through certain symptoms (e.g., poor sleep or fatigue).  
An unexpected finding of the current study was the decline of trait anxiety in patients 
over the course of treatment. This dissents the theoretical background, Spielberger’s anxiety 
model, which considers trait anxiety to be a stable personality characteristic, not likely to change 
over time (Spielberger and Reheiser, 2009; Spielberger, 1989; Spielberger et al., 1983). Research 
evidence facilitating the interpretation of this change in trait anxiety comes from qualitative 
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studies exploring the experience and sense-making of patients with cancer. In a longitudinal 
interview study of 12 women with breast cancer (McCann et al., 2010), their illness emerged as a 
life-altering experience: presenting as biographical disruption, patients had to renegotiate their 
identity to make the transition into a future of living with cancer. Similar profound adaptation 
processes have been shown in other studies of patients with prostate (Navon and Morag, 2004) 
and terminal cancer (Reeve et al., 2010). It seems likely that such far-reaching changes in a 
person’s life can affect personality traits like a person’s vulnerability to experience anxiety, too.  
An alternative field of research to considering when trying to explain the observed 
changes in trait anxiety over time is resilience research. Current evidence suggests that resilience 
as a baseline characteristic or trait may facilitate coping with cancer, but could also be an 
outcome of a successful adaptation to the ‘trauma’ of being diagnosed with and treated for 
cancer (Jacelon, 1997; Molina et al., 2014). As resilience is attended by positive emotional 
experiences and might be a more common reaction to traumatic experiences than generally 
believed (Bonanno, 2004), a decline in a persons’ vulnerability to experience anxiety over the 
course of cancer treatment is logically consistent.  
Clinical implications 
Our findings offer valuable evidence on how to best support patients undergoing 
chemotherapy, providing means of identifying those at greatest risk of experiencing anxiety and 
targeting interventions accordingly. Anxiety should be assessed before the first chemotherapy 
cycle as this is the most anxiety-provoking moment throughout a patient’s journey. Addressing 
fears at this stage seems the most promising time point to initiate change processes that should 
show positive effects later during treatment. Ensuring good preparation prior to the start of 
chemotherapy (Burish et al., 1991) and that patients get the support they need, including help 
with anxiety issues (Traeger et al., 2012), is essential. Psychosocial interventions, for example 
supportive counselling, coping or relaxation trainings, seem more suitable to manage fears in the 
long term than pharmacological treatments with less sustainable effects (Traeger et al., 2012).  
Patients with high trait anxiety are particularly likely to require additional, personality-
tailored support, as they tend to continue feeling more anxious throughout treatment. In line with 
Van Esch et al. (2011), screening for trait anxiety and, if necessary, psychological interventions 
are advisable prior to treatment to improve patients’ experiences, potentially reducing side-
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effects. To encourage patients’ tendency to adapt to their treatment and to feel less anxious over 
time, health care providers should take on a strengths-based perspective on human functioning 
and consider adjuvant psycho-social factors, for example building on existing social support 
(Lien et al., 2009), to foster resilience (Molina et al., 2014).  
Limitations and future research  
The current research was a secondary data analysis; hence, more focused research is 
needed to answer the proposed research questions. While presenting an economic approach that 
granted access to a large patient sample, not all variables that potentially influence state and trait 
anxiety were measured. Future studies should advance the current findings, researching the role 
of factors such as patients’ type of personality, coping strategies and social support on anxiety, as 
well as the link between trait anxiety, symptom burden and state anxiety. It would be of 
particular interest to focus on variables that, similarly to anxiety, potentially change over the 
course of treatment like self-efficacy and resilience.  
We also acknowledge the possibility that certain physical symptoms may generate greater 
anxiety than others. Yet the objective in this study was to consider multi-symptoms instead of 
single-symptom burden. Previous research has shown that multiple symptoms (some of them in 
clusters) may be experienced by the majority of patients receiving chemotherapy (Thomas et al., 
2014; Skerman et al., 2012), and it was this cumulative effect of multiple symptoms on anxiety 
levels that we wished to investigate here. Investigation of the links between single 
chemotherapy-related symptoms and state/trait anxiety levels is nevertheless warranted. 
To the authors’ knowledge, no other study has researched trait anxiety in patients 
undergoing chemotherapy in a longitudinal manner, which is a major advantage of the current 
research. However, the data was collected from a convenience sample and is therefore not 
representative of all patients with breast or colorectal cancer. It should be the aim of future 
research to test our findings within larger samples and other patient groups and to clarify the 
mechanism behind observed changes in this personality-like trait. It would be worth exploring if 
similar findings can be demonstrated for patients receiving a different form of cancer treatment. 
Investigating anxiety during chemotherapy in a first instance suggests itself insofar as this 
treatment causes higher anxiety levels than other treatment types (Lim et al., 2011). Similarly, 
researching different tumour groups is advisable as patients’ experiences differ for different 
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types of cancer (LeMasters et al., 2013), but results concerning patients with breast and 
colorectal cancer are particularly important considering their high incidence rates (Westlake and 
Cooper, 2008). Finally, interventions based on aforementioned suggestions should be verified in 
the future to optimise patient care. In particular, testing the effect of psychosocial interventions at 
the time point of diagnosis on subsequent anxiety seems like a worthwhile endeavour. This could 
strengthen the evidence base for anxiety treatment in cancer patients as called for by Traeger et 
al. (2012).   
Conclusions 
 The current study highlights the time point before the start of chemotherapy as extremely 
anxiety provoking. Patient support at this stage might foster an improvement in patients’ 
experiences of anxiety throughout treatment, in particularly for patients with high trait anxiety. 
Ensuring patients receive this kind of support could not only help reduce state anxiety throughout 
chemotherapy, but could also lower their vulnerability to react anxiously in the future, promoting 
resilience as result of their illness. 
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Tables and figures  
Table 1. Characteristics of the total group (N=140) and separately for the BC group (N=74) and 
the CRC group (N=52) at baseline.  
Characteristics Total group BC group CRC group 
 
Age (years)a 
 
 
55.96±10.4 
 
52.81±10.13 
 
60.58±9.14 
Gender: male/ femaleb 
  
29 (21.2)/ 108 (78.8) 2 (2.5) / 79 (97.5) 26 (47.3)/ 29 (52.7) 
Disease stage  
TNM UICC: I/ II/ III/ IVb 
 
11 (8.9)/ 58 (46.8)/ 51 (41.1)/ 
4 (3.2) 
8 (11.1)/ 47 (65.3)/ 17 
(23.6)/ 0  
3 (5.8)/ 11 (21.1)/ 34 (65.4)/ 
4 (7.7) 
Number of co-morbid 
illnesses: 0/ 1/ ≥2b 
 
50 (36.5)/ 39 (28.5)/ 48 
(35.0) 
38 (46.9)/ 23 (28.4)/ 20 
(24.7) 
11 (20.0)/ 16 (29.1)/ 28 
(50.9) 
ECOG status: 0/ 1/ 2 
 
92 (71.3)/ 35 (27.1)/ 2 (1.6) 62 (82.7)/ 12 (16.0)/ 1 (1.3) 29 (54.7)/ 23 (43.4)/ 1 (1.9) 
RSCL-Symptom 
scorea 
 
31.63± 6.07 31.31±6.10 32.18±6.06 
STAI-State scorea 
 
35.86±12.35 37.26±12.700 34.00±11.71 
STAI-Trait scorea 
 
34.75±10.21 35.42±10.38 34.00±9.96 
BC=breast cancer; CRC=colorectal cancer; TNM UICC=Tumour Node Metastasis Union International Contra la Cancrum; 
ECOG= Eastern Cooperative Oncology Group; RSCL=Rotterdam Symptom Checklist; STAI=State–Trait Anxiety Inventory.  
 
amean±SD. bn (%). 
 
 
 
Table 2. Changes in state/trait anxiety and symptom burden at each time point compared to 
baseline (mean±SD). 
 CTx1 CTx2 CTx3 CTx4 CTx5 CTx6 
 
STAI-State score 
 
 
35.86±12.35 
 
-3.08±9.63 
 
-2.33±11.16 
 
-3.86±11.49 
 
-3.97±11.06 
 
-4.66±11.09 
STAI-Trait score 
 
34.75±10.21 -0.58±7.48 0.15±7.24 -0.47±7.75 -2.08±6.44 -1.69±6.04 
RSCL Symptom 
burden score 
31.63± 6.07 0.83±7.14 0.82±7.46 1.97±8.66 2.06±6.32 3.00±7.28 
CTx – Chemotherapy cycle; STAI=State–Trait Anxiety Inventory. 
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Table 3. Mixed model results for the longitudinal relationship between baseline characteristics (predictor 
variables) and state anxiety/ trait anxiety as (dependent variables) as measured with the STAI. 
 Coefficient (SE) 
Variables   Means only model  Unconditional model  Conditional model  
State Anxiety 
Fixed effects 
     Intercept 
     Time (linear rate of change) 
Time invariant covariates - baseline 
     Gender 
     Cancer type 
     Age 
     Cancer stage 
     Comorbidities  
     ECOG status baseline 
Time invariant covariates - change 
     Time x Gender  
     Time x Cancer type 
     Time x Age 
     Time x Cancer stage 
     Time x Comorbidities  
     Time x ECOG status baseline 
Time variant covariates 
     RSCL-Symptom score 
Variance components 
     In intercept 
     In linear rate  
Goodness-of-fit deviance Model 
comparison (χ2 [df]) 
 
 
 
33.23 (0.92)** 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
104.17 (14.00)** 
 
 
34.91 (0.94)** 
-0.84 (0.20)** 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
99.46 (14.73)** 
1.94 (0.61)** 
 
46.3 [3]** 
 
 
 
19.83 (10.12) 
1.02 (2.09) 
 
4.59 (2.87) 
.943 (2.49) 
-0.02 (0.11) 
-2.91 (4.13) 
-0.25 (1.29) 
0.12 (2.26) 
 
-0.69 (0.61)  
-0.24 (0.54) 
-0.01 (0.02) 
-1.31 (0.04) 
-0.02 (0.28) 
0.60 (0.50) 
 
0.21 (0.06)** 
 
93.23 (15.09)** 
2.08 (0.68)** 
 
262.974 [13]** 
Trait Anxiety  
Fixed effects 
     Intercept 
     Time (linear rate of change) 
Time invariant covariates - baseline 
     Gender 
     Cancer type 
     Age 
     Cancer stage 
     Comorbidities  
     ECOG status baseline 
Time variant covariates 
     RSCL-Symptom score 
Variance components 
     In intercept 
     In linear rate  
Goodness-of-fit deviance Model 
comparison (χ2 [df]) 
 
 
 
34.10 (0.88)** 
 
 
 
 
 
 
 
 
 
 
 
98.81 (12.70)** 
 
 
34.79 (0.85)** 
-0.33 (0.12)* 
 
 
 
 
 
 
 
 
 
 
86.04 (11.92)** 
0.32 (0.23) 
 
17.708 [3]** 
 
 
27.34 (8.96)* 
1.18 (1.17) 
 
1.20 (2.56) 
-0.71 (2.22) 
-0.01 (0.10) 
-3.07 (3.66) 
0.70 (1.15) 
1.21 (2.01) 
 
0.18 (0.05)** 
 
79.18 (11.95)** 
0.05 (0.21) 
 
211.435 [13]** 
STAI=State-Trait Anxiety Inventory; SE=Standard Error; CI – Confidence interval; ECOG – Eastern Cooperative 
Oncology Group; RSCL=Rotterdam Symptom Checklist. *p≤0.001; **p<0.05.  
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Figure 1. Course of state and trait anxiety over the course of chemotherapy  
(Error bars: 95% CI; STAI=State–Trait Anxiety Inventory).  
 
